5.97
5.97 (0%)
As of Feb 14, 2025
Verastem, Inc. [VSTM]
Source:
Company Overview
Verastem, Inc. is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (“RAS”)/ mitogen activated pathway kinase (“MAPK”) pathway-driven cancers.
| Country | United States |
| Headquarters | needham, massachusetts |
| Phone Number | (781) 292-4200 |
| Industry | manufacturing |
| CEO | Daniel W. Paterson |
| Website | www.verastem.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $10 |
| Operating Profit | $-115 |
| Net Income | $-130.6 |
| Net Cash | $10 |
Profit Ratios
| Gross Margin | $10 |
| Operating Margin | -1,149.6 |
| Profit as % of Revenues | -7.7% |
| Profit as % of Assets | -104% |
| Profit as % of Stockholder Equity | 452.1% |
Management Effectiveness
| Return on Equity | 452.1% |
| Return on Assets | -128.7% |
| Turnover Ratio | 8% |
| EBITA | $-115 |
Balance Sheet and Cash Flow Measures
| Total Assets | $101.5 |
| Total Liabilities | $130.4 |
| Operating Cash Flow | $-104.8 |
| Investing Cash Flow | $60 |
| Financing Cash Flow | $54.8 |
